Clinical Trials Logo

Clinical Trial Summary

The team integrates experimental analyses of clinical and basic medicine and transgenic mice models. miR-29a acts a potent protective factor against excessive fibrosis in myofibroblasts of subacromial bursa tissue. Gain of miR-29a stabilizes tendon and synovial tissue homeostasis that alleviates tissue stiffness and maintains function.


Clinical Trial Description

Aims of first: The team will evaluate the associations among the mR-29a, miR-29b, miR-29c expression in subacromial bursa and subacromial fluid, incidence of shoulder stiffness, Constant scores, and VAS.

Aims of second: The team will isolate primary myofibroblast from subacromial bursa tissue as in vitro models and investigate the molecular events in the IL-1β modulation of miR-29a expression and the molecular mechanism underlying miR-29a inhibition of fibrotic matrix accumulation and apoptotic reactions in myofibroblast cultures. ;


Study Design


Related Conditions & MeSH terms

  • Stiffness of Shoulder, Not Elsewhere Classified

NCT number NCT02534558
Study type Interventional
Source Chang Gung Memorial Hospital
Contact Jih-Yang Ko, MD
Phone 886-7-731-7123
Email kojy@cgmh.org.tw
Status Recruiting
Phase N/A
Start date August 1, 2014
Completion date July 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT05540301 - Sleeper's and Adduction Stretch to Increase Shoulder ROM N/A
Recruiting NCT02450864 - The Biological Effect of ESWT and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness N/A